Guidelines of the German Neurological Society
The 2008 guidelines of the DGN include one chapter on the diagnosis of neuropathic pain, giving the following recommendations. 3 A detailed patient history with information not only about possible reasons for neuropathic pain but also about the characteristics of neuropathic pain and a thorough neurological examination are strongly recommended. The neurological examination should determine a somatosensory profile and delineate possible neurological deficits. It is also helpful to assess the degree and extent of plus and minus symptoms associated with neuropathic pain. Plus symptoms include spontaneous or evoked pain, itching, static or dynamic allodynia (i.e. pain on application of normally non-painful stimuli such as a light touch) or hyperalgesia (i.e. increased pain on application of painful stimuli such as pinprick); minus symptoms include hypesthesia or hypalgesia. For the assessment of pain intensity (including current intensity, maximum intensity and average intensity over a defined period), the application of visual or numerical rating scales (VRS and NRS, respectively) is recommended.
The degree of possible pain chronicity should also be investigated by pain chronification scales. For this purpose the Graded Chronic Pain Scale (GCPS) 5 or the German Mainzer-Chronifizierungsbogen 6 can be used. Self-employed pain diaries are recommended for tracking the temporal course of neuropathic pain in patients and for documentation of the consumption and effect of analgesic drugs over time. 
Guidelines of the European Federation of Neurological Societies
The One of the recommended main assessment questionnaires is the Neuropathic Pain Scale (NPS), 13 which however is said to lack some pain qualities frequently found in neuropathic pain. Therefore, the Pain Quality Assessment Scale (PQAS) 14 has been developed, but this questionnaire has not yet been used in blinded neuropathic pain trials.
An alternative questionnaire is the Neuropathic Pain Symptom
Inventory (NPSI), 15 which has been submitted for validation in 50
languages. The EFNS recommends the use of these screening tools to identify potential patients with neuropathic pain. However, since 10-20% of patients with neuropathic pain will not be detected by these screening tools alone, they do not replace the clinical evaluation of the patient. The NPS or the NPSI are recommended to evaluate the effects of treatment on neuropathic pain symptoms.
The EFNS guideline recommends that QST can be used in the clinic along with bedside tests to document the sensory profile of the patient. However, QST is not considered sufficient to distinguish non-neuropathic from neuropathic pain. QST is considered helpful to quantify treatment effects on allodynia and hyperalgesia. For the assessment of mechanical allodynia or hyperalgesia, the use of a brush and a high-intensity pinprick or von Frey filament is recommended. The systematic investigation of thermal stimuli
Neuropathic Pain Assessment -Overview of Existing Guidelines and Discussion for the Future is not yet considered sufficient to recommend these techniques in clinical practice.
The most extensively investigated methods of functional neuroimaging in the assessment of neuropathic pain are functional MRT (fMRT) and positron-emission tomography (PET). The data so far support the notion that spontaneous neuropathic pain is associated with a decrease in contralateral thalamic blood flow, whereas provoked neuropathic pain is associated with an increase in contralateral thalamic blood flow.
Functional imaging techniques are not yet recommended by the EFNS guidelines for routine investigation of patients with neuropathic pain.
Guidelines of the Neuropathic Pain Special Interest Group on Neuropathic Pain Assessment
The recently published 2010 NeuPSIG guidelines 2 on neuropathic pain assessment had several aims: to assess the incidence and prevalence of neuropathic pain; to evaluate the sensitivity of the methods available to investigate neuropathic pain; to evaluate the methods available for assessing neuropathic pain treatment and to propose future studies on unsolved topics in neuropathic pain.
Of the screening tools for neuropathic pain, the NeuPSIG guideline 
Conclusions and Future Challenges
Although the equipment for the assessment of neuropathic pain has been substantially replenished in recent years, further improvement is still needed. There is a lack of adequate tools for the assessment of Improving the methods will also give further insights into the pathophysiology of neuropathic pain. This in turn will help to improve the classification of pain syndromes that are not covered by the new definition of neuropathic pain, such as complex regional pain syndrome or fibromyalgia syndrome. n
